Skip to main content
. 2020 Oct 19;16(16):3184–3199. doi: 10.7150/ijbs.45505

Figure 5.

Figure 5

MPT0B291 reduces glioma growth in the xenograft animal model. (A) Representative IVIS200 images of xenografts treated with vehicle (Veh), MPT0B291 (25 mg/kg, p.o.), SAHA (150 mg/kg, p.o.) and TMZ (25 mg/kg, p.o.). (B) The bioluminescence flux of xenografts treated with vehicle, MPT0B291 (10 or 25 mg/kg, p.o.), SAHA (150 mg/kg, p.o.) and TMZ (25 mg/kg, p.o.) at d6, d13 and d16 is presented as mean ± SEM (n=4 in each group). (C) Kaplan-Meier survival curve of xenografts treated with vehicle, MPT0B291 (10 or 25 mg/kg, p.o.), SAHA (150 mg/kg, p.o.) and TMZ (25 mg/kg, p.o.), *p<0.005 versus Vehicle; p<0.005 versus SAHA (150). (D) The normalized bioluminescence flux (day13/day6) of xenograft treated with MPT0B291 (10 or 25 mg/kg, p.o.), TMZ (25 mg/kg, p.o.) and MPT0B291 plus TMZ is presented as as mean ± SEM (n=4 in each group). (E) Representative images of IHC for Ki67 (brown) and cleaved caspase-3 (brown) in brain section of sham mice and U-87MG-xenografts treated with or without MPT0B291. (Calibration = 50 µm).